🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

RecruitingNAAges 20 Years - anyAllE-DA Hospital
NCT05818072 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults with columnar-lined esophagus Exclusion Criteria: * A prior history of endoscopic treatment for Barrett's Esophagus * A prior history of upper gastrointestinal malignancy * A prior history of total or subtotal gastrectomy * Esophageal varices noted during the procedure * Uncontrolled coagulopathy * Taking antiplatelet drug or anticoagulant
💊

What it tests

  • One biopsy
  • Three biopsy
  • Seattle protocol
  • Endoscopy
📍

Where

1 site
E-DA Hospital
Kaohsiung City, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy